• Rani Therapeutics director Michelle Gilson filed an initial Form 3 disclosing a fully vested option for 12,500 Class A shares at USD 7.46.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001930862-26-000010), on August 04, 2026, and is solely responsible for the information contained therein.